Study in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and Outcomes (Betreat)

AstraZeneca

Status: Completed

Conditions: Severe Asthma

Study type: Observational

Funder types: Industry

Identifiers

NCT07159295

D3250R00088

Details and patient eligibility

About

Benralizumab is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β2-agonists. It has been reimbursed in Portugal as an add-on therapy since May 2019. In order of this, there is crucial need in Portugal to provide key real-word evidence on benralizumab therapy.

Full description

This is a real-world retrospective, multicentric, observational study, utilizing secondary data collection from medical records of adults patients (≥18 years) with severe asthma (maintenance treatment with high dose inhaled corticosteroids combined with long-acting agonist β2) and eosinophilic phenotype, who, at the discretion of the physician, received benralizumab accordingly to the clinical practice, in the period after the marketing authorization of benralizumab.

Enrollment: 74 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults patients with severe asthma treated with benralizumab, who had their first benralizumab dose between July 2019 and October 2020

  • Patients who have at least 1 benralizumab injection and with at least 3 months follow-up data from the first injection.
  • Give voluntary signed informed consent

Exclusion criteria

• Currently receiving benralizumab or any other biologic drug for the treatment of asthma in a clinical trial